联合应用肿瘤浸润淋巴细胞、白介素2治疗恶性脑肿瘤的临床研究  

Clinical Study of Combining Use of Tumor Infiltrating Lymphocytes (TIL) and Interleukin-2(IL-2) for the Treatment of Malignant Cerebral Tumor

作　　者：龚德生[1] 茅振华[1] 朱荣兴[1] 周建军[1] 傅震[2] 李洪福[2] 

机构地区：[1]苏州医学院附属第三医院神经外科,213003 [2]南京医科大学第一附属医院神经外科,213003

出　　处：《江苏医药》1998年第11期788-790,共3页Jiangsu Medical Journal

摘　　要：为延长恶性脑肿瘤患者的生存期，测定肿瘤浸润淋巴细胞（TIL）、白介素2（IL－2）在人体内杀肿瘤细胞的活性，在已经取得良好的实验室研究和动物实验研究的基础上，将TIL、IL-2联合应用于31例恶性脑肿瘤患者临床治疗。结果显示免疫治疗组与对照组1～3年生存率及死亡病例平均生存期均有显著差异。认为：从手术标本提取TIL，在体外经IL－2激活、培养、扩增3周，再回输入肿瘤手术残腔，能有效地杀灭残留的瘤细胞，可能是一种较为理想的恶性脑肿瘤的综合疗法。In order to prolong the survival period of malignant cerebral tumor patients, we determined the activity of TIL,IL-2 killing tumor cells inside of human body, that TIL in combination of IL-2 was clinically applied in 31 malignant cerebral tumor patients on the basis of previous good laboratory research results in animal experiments. This immunization therapy group revealed marked better 1, 2, 3 years of survival rate even including the average survival period of the dead patients. We saved the actived TIL from operation specimen, by means of three weeks culturing and expanding by IL-2 out side of human body, then injected back in to the postoperative cavity,so that the remained tumor cells could be effectively killed. And it is probably the ideal combined treatment method of malignant tumor of brain, as we would suggest here.

关 键 词：脑肿瘤 肿瘤浸润 淋巴细胞 免疫疗法 TIL IL-2 

分 类 号：R739.410.5[医药卫生—肿瘤] R730.51[医药卫生—临床医学]